Our Active Grants:
A Novel Deprescribing Intervention for Heart Failure with Preserved Ejection Fraction (HFpEF)
Agency: NIA
Project Period: 08/15/2020 – 05/31/2025
Principal Investigator(s): Parag Goyal, MD
Goal(s): To develop and study single-patient (N-of-1) trials as an intervention to promote shared decision making among older adults with heart failure with preserved ejection fraction.
N-of-1 Trials to Promote Deprescribing in Older Adults with Transthyretin Cardiac Amyloidosis
Agency: The U.S. Deprescribing Research Network
Project Period: 05/2023 – 04/2024
Principal Investigator(s): Parag Goyal, MD
Goal(s): To develop a shared decision making tool (N-of-trials) to facilitate medication optimization (and deprescribing) for older adults with cardiac amyloidosis.
Advancing the Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention
Agency: NIA
Project Period: 04/2023 - 03/2025
Principal Investigator(s): Parag Goyal, MD; Megan Shen, Ph.D. (Weill Cornell Medicine)
Goal(s): To pilot the "Conversations Helpful for Awareness of Illness Trajectory (CHAT)" intervention to improve communication about illness trajectory, and subsequently improve symptom burden and advance care planning among patients with heart failure with preserved ejection fraction (HFpEF).
Preventing Myocardial Events of Aging: A PREVENTABLE Ancillary Study (PRIME)
Agency: NIA
Project Period: 09/2023-08/2028
Principal Investigater: Parag Goyal, MD
Goal(s): To determine whether statins prevent incident HFpEF hospitalizations and AMI in older adults, and to determine the impact of relying on diagnosis codes to identify HFpEF and AMI.
Active Collaborative Grants:
Coronary Artery Calcium in the PRagmatic EValuation of evENTs And Benefits of Lipid lowering in the Elderly: CAC PREVENTABLE
Agency: National Heart, Lung, & Blood Institute
Project Period: 11/30/2023 - 07/31/2026
Principal Investigator(s): Melissa Daubert, MD (Duke University); Michael Blaha, MD (Johns Hopkins University), Nicholas Pajewski, PhD (Wake Forset University)
Goal(s): This PREVENTABLE ancillary study aims to explore the role of calcium score in evaluating cardiovascular events and the benefits of lipid-lowering interventions in elderly individuals.
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
Agency: NHLBI
Project Period: 09/2023 - 06/2028
Principal Investigator(s): Madeline Sterling, MD (Weill Cornell Medicine)
Goal(s): To dramatically improve care and outcomes for HF patients and produce novel insights for the dissemination and implementation of HHC nationally
Pragmatic Evaluation of Events and Benefits of Lipid-lowering in Older Adults
Agency: National Institute of Health
Project Period: 09/30/2019 - 08/31/2027
Principal Investigator(s): Karen Alexander, MD (Duke University); Walter Ambrosius Ph.D. (Wake Forest University); Adrian Hernandez, MD (Duke University); Jeff Williamson, MD (Wake Forest University)
Goal(s): To evaluate the efficacy of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Cardiac Magnetic Resonance for Tissue Characterization-Based Risk Stratification
Agency: NHLBI
Project Period: 09/01/2021 – 07/31/2026
Principal Investigator(s): Jiwon Kim, MD (Weill Cornell Medicine)
Goal(s): To utilize cardiac MRI to assess cardiac contractile function for prediction of long-term cardiopulmonary symptoms, effort tolerance, and prognosis for COVID-19 survivors.
Physical Rehabilitation for Older Patients with Acute HFpEF – The REHAB-HFpEF Trial
Agency: Wake Forest University Health Sciences
Project Period: 10/01/2022 – 09/30/2027
Principal Investigator(s): Dalane Kitzman, MD (Wake Forest University)
Goal(s): To determine whether the REHAB-HF intervention, compared with attention control usual care, will reduce the primary endpoint of combined all-cause rehospitalizations and all-cause mortality in older patients hospitalized with acute decompensated HFpEF at 6 months follow-up.
REasons for Geographic And Racial Differences in Stroke-Myocardial Infarction-4 (REGARDS-MI-4)
Agency: NHLBI
Project Period: 07/01/2022 – 06/30/2026
Principal Investigator(s): Monika Safford, MD (Weill Cornell Medicine); Emily Levitan, ScD (University of Alabama - Birmingham)
Goal(s): 1) To identify novel mechanisms leading to disparities in incident and recurrent CHD (congenital heart disease) and HF, and outcomes following CHD or HF events including reserve and resilience; 2) To adjudicate heart-related outcomes (CHD, HF hospitalizations, causes of death), link Medicare data, and make these data available to the scientific community; and 3) To build capacity in CHD and HF health disparities research through the mentorship of ESIs.
Improve the Meaning of Patient Reported Outcomes to Evaluate Effectiveness for Cardiac Care (IMPROVE-Cardiac Care)
Agency: NHLBI
Project Period: 07/01/2022 – 06/30/2027
Principal Investigator(s): Ruth Masterson Creber, Ph.D. (Columbia University)
Goal(s): To establish minimally important differences in specific cohorts of cardiac patients and to support the use of patient reported outcomes in clinical care.
Completed Grants:
Successful Aging and Cardiovascular Disease
Agency: American Heart Association
Project Period: 07/01/2020 – 06/30/2023
Principal Investigator(s): Parag Goyal, MD
Goal(s): To determine the impact of cardiovascular disease on successful aging, and identify factors of resilience.
Patient-Identified Contributors to Readmission Among Older Adults with Heart Failure
Agency: New York Academy of Medicine
Project Period: 07/01/2016 – 06/30/2017
Principal Investigator(s): Parag Goyal, MD
Goal(s): To better understand patient-reported experiences and contributors to rehospitalization among older adults with heart failure.
Delivery System Reform Incentive Payments (DSRIP)
Agency: New York State Department of Health
Project Period: 09/01/2017 – 04/30/2018
Clinical Lead(s): Parag Goyal, MD
Goal(s): To develop processes at New York Presbyterian Hospital—Weill Cornell that contribute to the broader restructure the health care delivery system with the primary goal of reducing avoidable hospital use.
Impact of Polypharmacy on Rehospitalization in Older Adults with Heart Failure
Agency: NIH/NIA
Project Period: 07/15/2017 – 05/30/2020 (NCE)
Principal Investigator(s): Parag Goyal, MD
Goal(s): To examine the association between polypharmacy and 30-day rehospitalization among older adults following a hospitalization for heart failure.
Management of Polypharmacy Among Older Adults Hospitalized for Heart Failure
Agency: Weill Cornell Medicine Department of Medicine
Project Period: 07/01/2017 – 06/30/2020
Principal Investigator(s): Parag Goyal, MD
Goal(s): To characterize harmful medication patterns (including potentially inappropriate medication use) among older adults with heart failure.
Heart Failure Preserved Ejection Fraction Program for the Aging Heart
Agency: Fan Fox & Leslie R. Samuels Foundation
Project Period: 07/01/2018 – 06/30/2020
Principal Investigator(s): Parag Goyal, MD
Goal(s): To develop a new clinical program and research infrastructure to provide dedicated subspecialty care to older adults with heart failure with preserved ejection fraction (HFpEF).
Safety of Neurohormonal Antagonist Initiation Among Older Adults
Agency: American Heart Association
Project Period: 07/01/2018 – 06/30/2021 (NCE)
Principal Investigator(s): Parag Goyal, MD
Goal(s): To examine the safety of starting multiple NHAs in older adults following a hospitalization for HF with reduced ejection fraction (HFrEF).
Impact of Beta-blocker on Physical Function in Heart Failure with Preserved Ejection Fraction (HFpEF)
Agency: New York Community Trust
Project Period: 10/08/2019 – 10/31/2022
Principal Investigator(s): Parag Goyal, MD
Goal(s): To examine the impact of beta-blockers on exercise parameters among older adults with heart failure with preserved ejection fraction (HFpEF).